$CARA
Cara Therapeutics, Inc.

2014 Form 10-K Financial Statement

#000119312515107249 Filed on March 27, 2015

View on sec.gov

Income Statement

Concept 2014 2013 Q4 2013 Q3
Revenue $3.177M $973.0K $1.018M
YoY Change -73.45% 69.67%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.200M $1.100M $800.0K
YoY Change 77.14% 57.14% -20.0%
% of Gross Profit
Research & Development $15.07M $2.000M $3.764M
YoY Change 73.49% 100.0% 370.5%
% of Gross Profit
Depreciation & Amortization $783.0K $200.0K $190.0K
YoY Change -0.76% 0.0% -24.0%
% of Gross Profit
Operating Expenses $21.25M $3.100M $4.559M
YoY Change 74.16% 72.22% 153.28%
Operating Profit -$18.07M -$3.541M
YoY Change 7525.32%
Interest Expense $126.0K $0.00 -$1.034M
YoY Change -103.35%
% of Operating Profit
Other Income/Expense, Net $126.0K
YoY Change -103.35%
Pretax Income -$17.95M -$2.100M -$4.575M
YoY Change 349.44% 16.67% 281.25%
Income Tax -$201.0K $0.00 $0.00
% Of Pretax Income
Net Earnings -$17.75M -$2.100M -$4.575M
YoY Change 347.77% 16.67% 281.25%
Net Earnings / Revenue -558.55% -215.83% -449.41%
Basic Earnings Per Share -$0.49 -$1.07
Diluted Earnings Per Share -$842.9K -$0.49 -$1.07
COMMON SHARES
Basic Shares Outstanding 20.97M shares 4.288M shares
Diluted Shares Outstanding 20.97M shares 4.288M shares

Balance Sheet

Concept 2014 2013 Q4 2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $52.70M $12.40M $17.70M
YoY Change 325.0% 1027.27%
Cash & Equivalents $52.70M $12.36M $17.73M
Short-Term Investments
Other Short-Term Assets $300.0K $2.100M $600.0K
YoY Change -85.71% 2000.0%
Inventory
Prepaid Expenses $2.140M
Receivables
Other Receivables
Total Short-Term Assets $53.20M $14.56M $18.30M
YoY Change 264.38% 1113.17%
LONG-TERM ASSETS
Property, Plant & Equipment $2.100M $2.825M $3.000M
YoY Change -25.0% -21.53%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $700.0K $700.0K $700.0K
YoY Change 0.0% 0.0%
Total Long-Term Assets $2.700M $3.525M $3.800M
YoY Change -22.86% -18.02%
TOTAL ASSETS
Total Short-Term Assets $53.20M $14.56M $18.30M
Total Long-Term Assets $2.700M $3.525M $3.800M
Total Assets $55.90M $18.08M $22.10M
YoY Change 208.84% 228.78%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $500.0K $676.0K $1.300M
YoY Change -28.57% 35.2%
Accrued Expenses $1.400M $1.300M $1.200M
YoY Change 7.69% 225.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $300.0K
YoY Change -100.0%
Long-Term Debt Due $0.00 $0.00
YoY Change -100.0%
Total Short-Term Liabilities $3.400M $5.433M $7.300M
YoY Change -37.04% 219.59%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $900.0K $1.100M $1.200M
YoY Change -18.18% -21.43%
Total Long-Term Liabilities $900.0K $1.100M $1.200M
YoY Change -18.18% -21.43%
TOTAL LIABILITIES
Total Short-Term Liabilities $3.400M $5.433M $7.300M
Total Long-Term Liabilities $900.0K $1.100M $1.200M
Total Liabilities $4.300M $6.600M $8.500M
YoY Change -34.85% 112.9%
SHAREHOLDERS EQUITY
Retained Earnings -$62.46M
YoY Change
Common Stock $8.381M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $51.70M -$54.08M -$52.00M
YoY Change
Total Liabilities & Shareholders Equity $55.90M $18.10M $22.10M
YoY Change 208.84% 229.09%

Cashflow Statement

Concept 2014 2013 Q4 2013 Q3
OPERATING ACTIVITIES
Net Income -$17.75M -$2.100M -$4.575M
YoY Change 347.77% 16.67% 281.25%
Depreciation, Depletion And Amortization $783.0K $200.0K $190.0K
YoY Change -0.76% 0.0% -24.0%
Cash From Operating Activities -$17.64M -$5.060M -$3.440M
YoY Change -723.32% 239.6% 282.22%
INVESTING ACTIVITIES
Capital Expenditures $42.00K -$10.00K $0.00
YoY Change 740.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Investing Activities -$40.00K -$10.00K $0.00
YoY Change 300.0% -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $100.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 57.99M -310.0K 0.000
YoY Change 588.72% -112.45%
NET CHANGE
Cash From Operating Activities -17.64M -5.060M -3.440M
Cash From Investing Activities -40.00K -10.00K 0.000
Cash From Financing Activities 57.99M -310.0K 0.000
Net Change In Cash 40.31M -5.380M -3.440M
YoY Change 258.63% -638.0% 739.02%
FREE CASH FLOW
Cash From Operating Activities -$17.64M -$5.060M -$3.440M
Capital Expenditures $42.00K -$10.00K $0.00
Free Cash Flow -$17.68M -$5.050M -$3.440M
YoY Change -725.91% 238.93% 282.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q3 cara Percentage Of Discount On Conversion Price
PercentageOfDiscountOnConversionPrice
0.10 pure
CY2014Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
29186929 shares
CY2014Q1 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
29186929 shares
CY2015Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
22824919 shares
CY2014Q2 dei Entity Public Float
EntityPublicFloat
226478179
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
-52064000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4097000
CY2012Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
26636118 shares
CY2012Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
26636118 shares
CY2012Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
26636118 shares
CY2012Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
58522000
CY2012Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
58530000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
-58133000
CY2012Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
76000
CY2012Q4 us-gaap Accumulated Amortization Deferred Finance Costs
AccumulatedAmortizationDeferredFinanceCosts
4000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1117000
CY2012Q4 cara Common Stock Issuable Upon Conversion
CommonStockIssuableUponConversion
11594757 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4288243 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4288243 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000 shares
CY2013Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
29186929 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
29402200 shares
CY2013Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
29186929 shares
CY2013Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
13821981 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0 shares
CY2013Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
65586000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
25560000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
5415000
CY2013Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
65969000
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5433000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
349000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
676000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62456000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
8377000
CY2013Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1958000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
-54075000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
55000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
739000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
3475000
CY2013Q4 us-gaap Accumulated Amortization Deferred Finance Costs
AccumulatedAmortizationDeferredFinanceCosts
117000
CY2013Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1139000
CY2013Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
83000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12357000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2825000
CY2013Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
67000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
25560000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
32000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
2947000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
85000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8240000
CY2013Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
61000
CY2013Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
11000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
21433000
CY2013Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
860000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
136000
CY2013Q4 us-gaap Assets
Assets
18083000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2013Q4 us-gaap Prepaid Insurance
PrepaidInsurance
34000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
14558000
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2140000
CY2013Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
700000
CY2013Q4 cara Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
262000
CY2013Q4 cara Prepaid Initial Public Offering Costs
PrepaidInitialPublicOfferingCosts
1833000
CY2013Q4 cara Accrued Research Projects
AccruedResearchProjects
405000
CY2013Q4 cara Liabilities Convertible Preferred Stock And Stockholders Equity
LiabilitiesConvertiblePreferredStockAndStockholdersEquity
18083000
CY2013Q4 cara Unamortized Incentive Allowance
UnamortizedIncentiveAllowance
790000
CY2013Q4 cara Common Stock Issuable Upon Conversion
CommonStockIssuableUponConversion
12554171 shares
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5750000 shares
CY2014Q1 cara Common Stock Shares Issued Upon Exercise By Underwriters
CommonStockSharesIssuedUponExerciseByUnderwriters
750000 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22802039 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22802039 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0 shares
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
10.08
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
19851 shares
CY2014Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0 shares
CY2014Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0 shares
CY2014Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
1898360 shares
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
32716000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6192000
CY2014Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2014Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
3398000
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
23000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Accrued Rent Noncurrent
AccruedRentNoncurrent
292000
CY2014Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
515000
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-80201000
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
131840000
CY2014Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1946000
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
51662000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
112000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
2539000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
740000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
266000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1452000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
913000
CY2014Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
874000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
886000
CY2014Q4 us-gaap Incentive From Lessor
IncentiveFromLessor
2127000
CY2014Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
504000
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
52663000
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
3768000
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2084000
CY2014Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
56000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
32716000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
27000
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
566000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3508000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
333000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
8276000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
27094000
CY2014Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
1018000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Deferred Rent
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDeferredRent
114000
CY2014Q4 us-gaap Assets
Assets
55934000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2014Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
200000
CY2014Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
18000
CY2014Q4 us-gaap Prepaid Insurance
PrepaidInsurance
92000
CY2014Q4 us-gaap Assets Current
AssetsCurrent
53150000
CY2014Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
287000
CY2014Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
700000
CY2014Q4 cara Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
177000
CY2014Q4 cara Accrued Research Projects
AccruedResearchProjects
549000
CY2014Q4 cara Liabilities Convertible Preferred Stock And Stockholders Equity
LiabilitiesConvertiblePreferredStockAndStockholdersEquity
55934000
CY2014Q4 cara Unamortized Incentive Allowance
UnamortizedIncentiveAllowance
582000
CY2014Q1 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
12554171 shares
CY2014Q3 cara Number Of Shares Issued Upon Exercise Of Warrant
NumberOfSharesIssuedUponExerciseOfWarrant
6383 shares
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5750000 shares
CY2014Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
63250000
CY2014Q1 cara Proceeds From Issuance Initial Public Offering Net Of Offering Costs Paid
ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCostsPaid
56297000
CY2014Q1 cara Underwriting Discounts And Commissions
UnderwritingDiscountsAndCommissions
6953000
CY2013Q2 cara Probability Of Closing Equity Offering
ProbabilityOfClosingEquityOffering
0.00 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
4133138 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.4990 pure
CY2013Q4 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
311000
CY2013 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0075 pure
CY2013 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
2829000
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0603 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.0000 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0142 pure
CY2013 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2013 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4133138 shares
CY2013 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.1204 pure
CY2013 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4133138 shares
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
4466000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
75000
CY2013 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
311000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
667000
CY2013 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
307000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3993000
CY2013 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
3888000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-237000
CY2013 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-3756000
CY2013 us-gaap Revenues
Revenues
11964000
CY2013 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
70000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-3963000
CY2013 us-gaap Interest Paid
InterestPaid
37000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
123000
CY2013 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
1736000
CY2013 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
30000
CY2013 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
3432000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
123000
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
789000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
3475000
CY2013 us-gaap Operating Expenses
OperatingExpenses
12201000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8685000
CY2013 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
117000
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2013 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
0
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-5000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-30000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
123000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2013 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2013 cara Deferred Rent Liability Benefit
DeferredRentLiabilityBenefit
238000
CY2013 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1462000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3516000
CY2013 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
722000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
11240000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-30000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
616000
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
8416000
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-30000
CY2013 cara Proceeds From Issuance Of Debt And Equity Financing Prior To Initial Public Offering
ProceedsFromIssuanceOfDebtAndEquityFinancingPriorToInitialPublicOffering
73309000
CY2013 cara Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-3072000
CY2013 cara Adjustment For Fair Value Liability Under License Agreement
AdjustmentForFairValueLiabilityUnderLicenseAgreement
35000
CY2013 cara Collaborative Revenue
CollaborativeRevenue
2225000
CY2013 cara Extinguishment Of Preferred Stock
ExtinguishmentOfPreferredStock
891000
CY2013 cara Net Income Loss Available To Common Stockholders Basic And Diluted Per Share
NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedPerShare
-0.74
CY2013 cara License And Milestone Fees Revenue
LicenseAndMilestoneFeesRevenue
9637000
CY2013 cara Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure
CY2013 cara Accrued Interest And Amortization Of Beneficial Conversion Feature On Promissory Notes
AccruedInterestAndAmortizationOfBeneficialConversionFeatureOnPromissoryNotes
3605000
CY2013 cara Effective Income Tax Rate Reconciliation Stock Option Shortfalls And Cancellations
EffectiveIncomeTaxRateReconciliationStockOptionShortfallsAndCancellations
0.0000 pure
CY2013 cara Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Or Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesOrIssues
0
CY2013 cara Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gains Losses Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainsLossesNet
-76000
CY2013 cara Common Stock Reserved For Exercise Of Stock Options
CommonStockReservedForExerciseOfStockOptions
1247959 shares
CY2013 cara Common Stock Reserved For Exercise Of Warrants
CommonStockReservedForExerciseOfWarrants
19851 shares
CY2013 cara Clinical Compound Revenue
ClinicalCompoundRevenue
102000
CY2014 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.649 pure
CY2014 dei Document Type
DocumentType
10-K
CY2014 dei Entity Registrant Name
EntityRegistrantName
Cara Therapeutics, Inc.
CY2014 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2014 dei Trading Symbol
TradingSymbol
CARA
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.09
CY2014 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2014 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2004-07-02
CY2014 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2014 us-gaap Description Of Defined Contribution Pension And Other Postretirement Plans
DescriptionOfDefinedContributionPensionAndOtherPostretirementPlans
All employees over the age of 21 are eligible to participate in the plan after three consecutive months of service.
CY2014 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0112 pure
CY2014 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y2M27D
CY2014 us-gaap Income Tax Examination Description
IncomeTaxExaminationDescription
Tax years 2007 through 2014 remain open to U.S. federal and state tax examinations.
CY2014 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2014 us-gaap Nature Of Operations
NatureOfOperations
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt"> <b>1. Business</b></p> <!-- xbrl,body --> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Cara Therapeutics, Inc. (the &#x201C;Company&#x201D;) is a clinical-stage biopharmaceutical corporation formed on July&#xA0;2, 2004. The Company is focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors. The Company&#x2019;s primary activities to date have been organizing and staffing the Company, developing its product candidates, including conducting preclinical studies and clinical trials of CR845-based product candidates and raising capital.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company&#x2019;s registration statement on Form S-1 (File No 333-192230) relating to its initial public offering (&#x201C;IPO&#x201D;) was declared effective by the Securities and Exchange Commission on January&#xA0;30, 2014. The Company registered the offering and sale of 5,750,000 shares of common stock (including 750,000 shares upon exercise of an option by the underwriters) at a public offering price of $11.00 per share for an aggregate offering price of $63,250. As a result of the IPO, the Company received net proceeds of $56,297 after deducting $6,953 of underwriting discounts and commissions and offering expenses paid by the Company.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> Prior to the IPO, the Company raised several rounds of equity financing and issued debt, resulting in aggregate net proceeds of approximately $73,309, including $7,642 in connection with a Stock Purchase Agreement, which the Company entered into with Maruishi Pharmaceutical Co., Ltd. (&#x201C;Maruishi&#x201D;) in April 2013. In addition, in April&#xA0;2013, the Company entered into a License Agreement with Maruishi, which added $15,000&#xA0;in cash (see Note&#xA0;11, <i>Collaborations</i>).</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> As of December&#xA0;31, 2014, the Company had unrestricted cash and cash equivalents of $52,663 and an accumulated deficit of $80,201. The Company has incurred substantial losses and negative cash flows from operations in nearly every fiscal period since inception, and expects operating losses and negative cash flows to continue into the foreseeable future. The Company recognized net loss available to common stockholders of $17,745 and had net cash flows used in operating activities of $17,642 for the year ended December&#xA0;31, 2014. The Company expects that cash and cash equivalents at December&#xA0;31, 2014 will be sufficient to fund its operations beyond one year.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 12pt; TEXT-INDENT: 4%"> The Company is subject to risks common to other life science companies including, but not limited to, uncertainty of product development and commercialization, lack of marketing and sales history, development by its competitors of new technological innovations, dependence on key personnel, market acceptance of products, product liability, protection of proprietary technology, ability to raise additional financing, and compliance with Food and Drug Administration (&#x201C;FDA&#x201D;) and other government regulations. If the Company does not successfully commercialize any of its product candidates, it will be unable to generate recurring product revenue or achieve profitability.</p> </div>
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-17642000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00 pure
CY2014 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
2.5 pure
CY2014 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-2.5 reverse stock split
CY2014 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0523 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.0000 pure
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 6pt"> <i>Use of Estimates</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with generally-accepted accounting principles in the United States (&#x201C;GAAP&#x201D;) requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities, as of the date of the financial statements as well as the reported amounts of revenues and expenses during the reporting period. Actual results could differ materially from the Company&#x2019;s estimates and assumptions. Significant estimates include useful lives of fixed assets, the periods over which certain revenues will be recognized, including licensing and collaborative revenue recognized from non-refundable up-front and milestone payments, the determination of prepaid research and development clinical costs and accrued research projects, the amount of non-cash compensation costs related to share-based payments to employees and non-employees and the periods over which those costs are expensed and the likelihood of realization of deferred tax assets.</p> </div>
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20965935 shares
CY2014 dei Document Period End Date
DocumentPeriodEndDate
2014-12-31
CY2014 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3988 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0057 pure
CY2014 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2014 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 Segments
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0164 pure
CY2014 dei Amendment Flag
AmendmentFlag
false
CY2014 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
20965935 shares
CY2014 us-gaap Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
2014-07-31
CY2014 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
CY2014 dei Entity Central Index Key
EntityCentralIndexKey
0001346830
CY2014 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2014 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0303 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.713 pure
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0272 pure
CY2014 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 0pt"> <i>Concentration of Credit Risk</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Financial instruments, which potentially subject the Company to significant concentration of credit risk, consist primarily of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</p> </div>
CY2014 us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 4%; MARGIN-TOP: 18pt"> <i>Reclassifications</i></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> Certain revenue within the Statement of Operations has been reclassified from Collaborative revenue to Clinical compound revenue to conform to the current year presentation.</p> </div>
CY2014 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2014 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
20965935 shares
CY2014 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities Net Of Adjustments
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesNetOfAdjustments
65586000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
393000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
7156000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-17946000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
128000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-18072000
CY2014 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
126000
CY2014 us-gaap Royalty Revenue
RoyaltyRevenue
0
CY2014 us-gaap Revenues
Revenues
3177000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
42000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-17745000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1371000
CY2014 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-388000
CY2014 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
139000
CY2014 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1371000
CY2014 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2014 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
783000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-2023000
CY2014 us-gaap Operating Expenses
OperatingExpenses
21249000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15068000
CY2014 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
40306000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-201000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
643000
CY2014 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
57990000
CY2014 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
100000
CY2014 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
65586000
CY2014 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-201000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-42000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
128000
CY2014 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-201000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6181000
CY2014 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-12000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
1371000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2055000
CY2014 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2014 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2014 cara Deferred Tax Expense Benefit From Stock Options Exercised
DeferredTaxExpenseBenefitFromStockOptionsExercised
-401000
CY2014 cara Highly Liquid Investments Original Maturity Period Description
HighlyLiquidInvestmentsOriginalMaturityPeriodDescription
Three months or less
CY2014 cara Deferred Rent Liability Benefit
DeferredRentLiabilityBenefit
265000
CY2014 cara Completion Date Of Initial Public Offering One
CompletionDateOfInitialPublicOfferingOne
2014-02-05
CY2014 cara Preferred Stock Conversion Date
PreferredStockConversionDate
2014-02-05
CY2014 cara Percentage Of Research And Development Tax Credits Exchanged For Cash
PercentageOfResearchAndDevelopmentTaxCreditsExchangedForCash
0.65 pure
CY2014 cara Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-17745000
CY2014 cara Proceeds From Issuance Initial Public Offering Net Of Offering Costs Paid
ProceedsFromIssuanceInitialPublicOfferingNetOfOfferingCostsPaid
57762000
CY2014 cara Collaborative Revenue
CollaborativeRevenue
2201000
CY2014 cara Net Income Loss Available To Common Stockholders Basic And Diluted Per Share
NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedPerShare
-0.85
CY2014 cara Stockholder Equity Reverse Stock Split Effective Date
StockholderEquityReverseStockSplitEffectiveDate
2014-01-16
CY2014 cara Non Cash Or Part Non Cash Prepaid Initial Public Offering Costs Offset Against Proceeds Of Initial Public Offering
NonCashOrPartNonCashPrepaidInitialPublicOfferingCostsOffsetAgainstProceedsOfInitialPublicOffering
1465000
CY2014 cara License And Milestone Fees Revenue
LicenseAndMilestoneFeesRevenue
302000
CY2014 cara Deferred Tax Assets Valuation Allowance Percentage
DeferredTaxAssetsValuationAllowancePercentage
1.00 pure
CY2014 cara Stock Issued During Period Value Warrants Exercised Cashless
StockIssuedDuringPeriodValueWarrantsExercisedCashless
0
CY2014 cara Effective Income Tax Rate Reconciliation Stock Option Shortfalls And Cancellations
EffectiveIncomeTaxRateReconciliationStockOptionShortfallsAndCancellations
-0.0069 pure
CY2014 cara Lessee Leasing Arrangements Operating Leases Expiration Date
LesseeLeasingArrangementsOperatingLeasesExpirationDate
2017-10
CY2014 cara Lessee Leasing Arrangements Operating Leases Renewal Term Description
LesseeLeasingArrangementsOperatingLeasesRenewalTermDescription
The lease is renewable thereafter for two successive terms of five years.
CY2014 cara Common Stock Reserved For Exercise Of Stock Options
CommonStockReservedForExerciseOfStockOptions
1898360 shares
CY2014 cara Clinical Compound Revenue
ClinicalCompoundRevenue
674000
CY2012 us-gaap Incremental Common Shares Attributable To Conversion Of Debt Securities
IncrementalCommonSharesAttributableToConversionOfDebtSecurities
0 shares
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.0049 pure
CY2012 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0 shares
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6031000
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0560 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.0327 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
3299993 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.3789 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.0195 pure
CY2012 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
0 shares
CY2012 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3299993 shares
CY2012 us-gaap Incremental Common Shares Attributable To Conversion Of Preferred Stock
IncrementalCommonSharesAttributableToConversionOfPreferredStock
0 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.3400 pure
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.0000 pure
CY2012 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3299993 shares
CY2012 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
86000
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
65000
CY2012 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
446000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-6302000
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-286000
CY2012 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
55000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-6236000
CY2012 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-66000
CY2012 us-gaap Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
-294000
CY2012 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-18000
CY2012 us-gaap Revenues
Revenues
1190000
CY2012 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
47000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-6271000
CY2012 us-gaap Interest Paid
InterestPaid
20000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
61000
CY2012 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-73000
CY2012 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
511000
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
-31000
CY2012 us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-8000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
61000
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1021000
CY2012 us-gaap Operating Expenses
OperatingExpenses
7426000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4597000
CY2012 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
4000
CY2012 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
0
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2980000
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-31000
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
618000
CY2012 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
0
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
2540000
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
86000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
511000
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
55000
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
-31000
CY2012 us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
2538000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2829000
CY2012 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1311000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
61000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
10000
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
0
CY2012 cara Deferred Rent Liability Benefit
DeferredRentLiabilityBenefit
214000
CY2012 cara Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-6271000
CY2012 cara Adjustment For Fair Value Liability Under License Agreement
AdjustmentForFairValueLiabilityUnderLicenseAgreement
25000
CY2012 cara Net Income Loss Available To Common Stockholders Basic And Diluted Per Share
NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedPerShare
-1.90
CY2012 cara License And Milestone Fees Revenue
LicenseAndMilestoneFeesRevenue
1190000
CY2012 cara Accrued Interest And Amortization Of Beneficial Conversion Feature On Promissory Notes
AccruedInterestAndAmortizationOfBeneficialConversionFeatureOnPromissoryNotes
25000
CY2012 cara Effective Income Tax Rate Reconciliation Stock Option Shortfalls And Cancellations
EffectiveIncomeTaxRateReconciliationStockOptionShortfallsAndCancellations
-0.0254 pure
CY2013Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.48
CY2013Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.48
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1748000
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-1748000
CY2014Q1 us-gaap Revenues
Revenues
178000
CY2014Q1 cara Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-3383000
CY2014Q1 cara Net Income Loss Available To Common Stockholders Basic And Diluted Per Share
NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedPerShare
-0.22
CY2013Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.33
CY2013Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.34
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
5424000
CY2013Q2 us-gaap Revenues
Revenues
9973000
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1475000
CY2013Q2 us-gaap Participating Securities Distributed And Undistributed Earnings Loss Basic
ParticipatingSecuritiesDistributedAndUndistributedEarningsLossBasic
3869000
CY2014Q2 us-gaap Revenues
Revenues
960000
CY2014Q2 cara Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-3645000
CY2014Q2 cara Net Income Loss Available To Common Stockholders Basic And Diluted Per Share
NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedPerShare
-0.16
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.07
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.07
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4575000
CY2013Q3 us-gaap Revenues
Revenues
1018000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4575000
CY2014Q3 us-gaap Revenues
Revenues
1125000
CY2014Q3 cara Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-6545000
CY2014Q3 cara Net Income Loss Available To Common Stockholders Basic And Diluted Per Share
NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedPerShare
-0.29
CY2013Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.49
CY2013Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.49
CY2013Q4 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-2093000
CY2013Q4 us-gaap Revenues
Revenues
973000
CY2013Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-2093000
CY2014Q4 us-gaap Revenues
Revenues
914000
CY2014Q4 cara Net Income Loss Available To Common Stockholders Basic And Diluted
NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted
-4172000
CY2014Q4 cara Net Income Loss Available To Common Stockholders Basic And Diluted Per Share
NetIncomeLossAvailableToCommonStockholdersBasicAndDilutedPerShare
-0.18

Files In Submission

Name View Source Status
0001193125-15-107249-index-headers.html Edgar Link pending
0001193125-15-107249-index.html Edgar Link pending
0001193125-15-107249.txt Edgar Link pending
0001193125-15-107249-xbrl.zip Edgar Link pending
cara-20141231.xml Edgar Link completed
cara-20141231.xsd Edgar Link pending
cara-20141231_cal.xml Edgar Link unprocessable
cara-20141231_def.xml Edgar Link unprocessable
cara-20141231_lab.xml Edgar Link unprocessable
cara-20141231_pre.xml Edgar Link unprocessable
d841355d10k.htm Edgar Link pending
d841355dex1014.htm Edgar Link pending
d841355dex231.htm Edgar Link pending
d841355dex311.htm Edgar Link pending
d841355dex312.htm Edgar Link pending
d841355dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g841355g25x38.jpg Edgar Link pending
g841355g30v73.jpg Edgar Link pending
g841355g42v04.jpg Edgar Link pending
g841355g43f48.jpg Edgar Link pending
g841355g44x27.jpg Edgar Link pending
g841355g47v13.jpg Edgar Link pending
g841355g48n42.jpg Edgar Link pending
g841355g54b93.jpg Edgar Link pending
g841355g54d05.jpg Edgar Link pending
g841355g56n83.jpg Edgar Link pending
g841355g65k27.jpg Edgar Link pending
g841355g77d62.jpg Edgar Link pending
g841355g84m24.jpg Edgar Link pending
g841355g92f53.jpg Edgar Link pending
g841355g95a38.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending